Payment overview · 2025
General Payments
$540.29
22 reported records · 16 companies
Healthcare provider profile · identity verified
Cong Thanh Phan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · RANCHO CUCAMONGA, CA · NPI 1386778033
Verified facts
What the public records show
CMS Open Payments records show Cong Thanh Phan, M.D. received $540.29 in general payments during 2025 across 22 reported records.
PFIZER INC. accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Jardiance, Linzess, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Lantus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.36 | 15.8% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $69.07 | 12.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.21 | 7.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $40.65 | 7.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.30 | 6.9% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $33.26 | 6.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $30.57 | 5.7% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $26.56 | 4.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.30 | 4.9% | 1 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $25.04 | 4.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.73 | 4.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.13 | 4.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.78 | 3.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.59 | 3.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.36 | 3.4% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $15.38 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $540.29 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $69.07 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $63.64 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $50.43 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.65 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.30 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.30 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $33.26 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $30.57 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.40 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ALK-Abello, Inc | $25.04 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 118 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 61 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
118 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 648 | 192 |
| Losartan Potassium | Losartan Potassium | 553 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 535 | 162 |
| Metformin Hcl | Metformin Hcl | 506 | 144 |
| Gabapentin | Gabapentin | 406 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 380 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 344 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 117 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 76 |
| Montelukast Sodium | Montelukast Sodium | 206 | 65 |
| Famotidine | Famotidine | 184 | 49 |
| Lisinopril | Lisinopril | 177 | 48 |
| Carvedilol | Carvedilol | 176 | 61 |
| Simvastatin | Simvastatin | 175 | 52 |
| Omeprazole | Omeprazole | 174 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 165 | 67 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 160 | 86 |
| Trazodone Hcl | Trazodone Hcl | 145 | 33 |
| Alendronate Sodium | Alendronate Sodium | 142 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 44 |
| Furosemide | Furosemide | 137 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 136 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 40 |
| Jardiance | Empagliflozin | 122 | 27 |
| Mirtazapine | Mirtazapine | 120 | 36 |
| Januvia | Sitagliptin Phosphate | 119 | 21 |
| Eliquis | Apixaban | 118 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 117 | 30 |
| Donepezil Hcl | Donepezil Hcl | 114 | 26 |
| Ibuprofen | Ibuprofen | 110 | 54 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 47 |
| Prednisone | Prednisone | 93 | 66 |
| Azithromycin | Azithromycin | 89 | 81 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 28 |
| Cephalexin | Cephalexin | 82 | 71 |
| Farxiga | Dapagliflozin Propanediol | 82 | 17 |
| Lorazepam | Lorazepam | 81 | 25 |
| Potassium Chloride | Potassium Chloride | 81 | 30 |
| Allopurinol | Allopurinol | 79 | 24 |
| Ezetimibe | Ezetimibe | 76 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 73 | 16 |
| Clonidine Hcl | Clonidine Hcl | 71 | 35 |
| Lactulose | Lactulose | 71 | 43 |
| Xarelto | Rivaroxaban | 69 | 21 |
| Benazepril Hcl | Benazepril Hcl | 68 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 66 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 24 |
| Linzess | Linaclotide | 61 | 15 |
| Naproxen | Naproxen | 61 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 17 |
| Atenolol | Atenolol | 60 | 17 |
| Metformin Hcl Er | Metformin Hcl | 60 | 22 |
| Glipizide | Glipizide | 59 | 13 |
| Meloxicam | Meloxicam | 58 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 26 |
| Finasteride | Finasteride | 56 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 16 |
| Levetiracetam | Levetiracetam | 54 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 52 | 21 |
| Baclofen | Baclofen | 51 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 51 | 17 |
| Olopatadine Hcl | Olopatadine Hcl | 51 | 12 |
| Colchicine | Colchicine | 50 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 16 |
| Tramadol Hcl | Tramadol Hcl | 49 | 14 |
| Ozempic | Semaglutide | 47 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Loperamide | Loperamide Hcl | 45 | 17 |
| Nifedipine Er | Nifedipine | 45 | 14 |
| Creon | Lipase/Protease/Amylase | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 38 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 42 | 26 |
| Sertraline Hcl | Sertraline Hcl | 42 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 40 | suppressed |
| Novolin R | Insulin Regular, Human | 40 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Alprazolam | Alprazolam | 37 | 15 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | 11 |
| Temazepam | Temazepam | 35 | 11 |
| Fluocinonide | Fluocinonide | 34 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | 23 |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Scopolamine | Scopolamine | 29 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | 12 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 14 |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Glucagon Emergency Kit | Glucagon | 18 | suppressed |
| Humulin R | Insulin Regular, Human | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Riluzole | Riluzole | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Proctozone-Hc | Hydrocortisone | 11 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $540.29 · 22 records | PFIZER INC. | ABRYSVO, ACCRUFER, BREZTRI, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GARDASIL 9, IBSRELA, JARDIANCE, LINZESS, M-M-R II, NEFFY, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA, ROTATEQ, Senza, TZIELD, The Cologuard Plus Collection Kit, VAXELIS, VAXNEUVANCE, Wegovy, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error